Basic Information
| LncRNA/CircRNA Name | CCAT1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000247844 |
| Refseq | NR_108049 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qRT-PCR, Western blot |
| Sample | PCa tissues,cell lines (PC3 and DU145) |
| Expression Pattern | up-regulated |
| Function Description | FSCN1 restoration attenuated miR-24-3p-mediated inhibition of PTX resistance. Besides, FSCN1 level was enhanced in PCa and PTX-resistant PCa cells and regulated by CCAT1 and miR-24-3p. |
| Pubmed ID | 32089062 |
| Year | 2020 |
| Title | Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1 |
External Links
| Links for CCAT1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |